Literature DB >> 32489374

Marshallagia marshalli Antigen Strengthens Dendritic Cell Mediated T Lymphocyte Regulation on Asthmatic Patients.

Fatemeh Hemati1, Majid Mirsadraei2, Milad Hemati3, Hadi Mohebalian1, Hassan Borji1.   

Abstract

BACKGROUND: The current study was conducted to investigate the antigenic effect of Marshallagia marshalli on the treatment of asthma by measuring the secreted inhibitory cytokine.
METHODS: Case patients and controls were selected from clinics in Mashhad, Khorasan Razavi Province, Northeastern Iran in 2017-18. In this experimental study, peripheral blood mononuclear cells (PBMCs) were isolated from 15 patients with asthma and 10 healthy controls and were cultured. PBMCs were then converted to tolerogenic DCs through exposure to GM-CSF, IL-4 and M. marshalli antigen. Then, tolerogenic DCs were exposed to autologous T cells for five days and finally, the level of secreted TGF-β1 was measured.
RESULTS: The mean TGF-β1 level in the control and control groups was 210.2 ± 8.2 and 225.4 ± 6.1 pq/ml, respectively. The results showed that TGF-β1 levels in both groups significantly increased in both groups (P<0.001). In addition, TGF-β1 levels in the case group were significantly higher than the control group (P<0.001).
CONCLUSION: M. marshalli antigen increase the level of TGF-β1 and can create antigen-bearing dendritic cells and shift T lymphocytes to the regulatory type. This parasite can be used in dendritic cell therapy to control allergic diseases. Copyright© Iranian Society of Parasitology & Tehran University of Medical Sciences.

Entities:  

Keywords:  Asthma; Dendritic cells; Marshallagia marshalli; T-Lymphocytes

Year:  2020        PMID: 32489374      PMCID: PMC7244837     

Source DB:  PubMed          Journal:  Iran J Parasitol        ISSN: 1735-7020            Impact factor:   1.012


Introduction

Asthma is a complex and chronic inflammatory disease that affects more than 300 million people worldwide, and the number of infected people is increasing (1–3). This disease is accompanied by pulmonary inflammation, increased mucus secretion, reversible airway obstruction and wheezing (4, 5). Despite the considerable effect of current treatments, including corticosteroids and β2 agonists in most patients, there is no definitive treatment for this condition (4–6). In addition, the administration of systemic corticosteroids causes many side effects in patients who are resistant to the treatment (7, 8). Therefore, there is always a need for new treatments. The inflammation caused by asthma is originated from Th2 lymphocytes, which secrete a group of cytokines including IL-5, IL-4, IL-3, IL-13 and GM-CSF (2, 9, 10). Th2 cytokines are responsible for the regular management of an allergic inflammatory cascade that occurs in asthma, such as changing the class of secretory antibodies from plasma cells to IgE (IL-13 and IL-4), the differentiation of mast cells (IL-3 and IL-4 and IL-13), maturation and survival of eosinophils (IL-3, IL-5 and GM-CSF) and summons of basophils (IL-3 and GMCSF) (11–13). The prevalence of asthma in developed countries is higher than in developing countries, which, based on the hygiene hypothesis, is due to the reduction of contamination with bacteria and worm, and high standards of health in developed countries (14–16). Worms have infected about one-fourth of the world's population and rarely cause death. There have been many advances in perceiving the host-parasite relationship and the involved cellular and molecular mechanisms. The mechanisms include the induction of IL-10 and TGF β regulatory cytokines and the summons of DC4+CD25+FOXP3 T cell (T-reg) and the activity of anti-inflammatory alternative macrophage phenotype (17, 18). Many studies have been conducted regarding the positive effects of different types of worms on controlling allergic diseases proven the hygiene hypothesis. In developing countries, contamination with worm parasites has been associated with a reduction in the incidence of allergies, asthma and autoimmune diseases (19, 20). Nematode parasites such as Marshallagia marshalli may increase their survival by shifting immune responses to regulatory immunity (18, 21). For this reason, chronic worm infections may protect the host against allergic diseases due to extensive immunosuppression. This extensive immunosuppression can generally lead to a decrease in T cell responsiveness through the activity of T-reg cells and by regulating the effects of immune cells such as macrophages, dendritic cells, and topical stromal cells (21, 22). According to the results of research on different types of worms and the observation of regulatory effects in their inflammatory responses, a hypothesis arises that states dendritic cells and T lymphocytes can shift to dendritic toluene cells and regulatory T cell using worm antigens (23, 24). This process is effective in treating autoimmune and inflammatory diseases. For this reason, dendritic cell therapy has been used to treat many diseases, such as cancers in recent years (25–28). Dendritic cells are the only cells that can activate the T lymphocyte as the antigen-presenting cells, and shift the T lymphocytes into helper T lymphocytes (25, 27). Nowadays, DCs are used to produce vaccines for the treatment of many diseases (29, 30). However, the hypothesis that states parasitic antigens can be used to treat allergic diseases has not been definitively proved yet. In this study, tolerogenic dendritic cells and regulatory T lymphocytes were produced using M. marshalli antigens and we attempted to investigate the antigenic effect of this parasite on the treatment of asthma by measuring the secreted inhibitory cytokine.

Materials and Methods

Case patients and controls were selected from clinics in Mashhad in Khorasan Razavi Province in Northeastern Iran in 2017–18. In this experimental study, 25 samples including 15 patients with asthma as case group and 10 healthy subjects as control group were randomly included in the study. The selection of samples in the case group was confirmed through examination by asthma and allergy specialist. The inclusion criteria were suffering from various underlying diseases such as autoimmune diseases, immunodeficiency, genetic problems, malignancy, and viral diseases. Then, 5 ml peripheral blood was collected from each sample and after isolating the PBMCs using Falcon, the monocyte cells were cultured in a 25 ml flask. A written informed consent was obtained from each patient before entering the study. The human investigation committee at Medical University of Mashhad approved the study protocol.

Preparation of somatic M. marshalli antigens

First, a large number of contaminated rennet were transferred from Industrial slaughterhouse of Mashhad to the Parasitology Laboratory of the Faculty of Veterinary Medicine of Ferdowsi University of Mashhad. The contents of the rennet were cleared and the contents were poured into a plate containing PBS. Subsequently, the mature male M. marshalli parasites were identified and isolated based on their morphology using loop device. They were then washed with sterile PBS solution during 4 steps. Then, the worms were fragmented inside a sterile petri dish using scalpel and were transferred into sterile microtubules. It was then homogenized several times with homogenizer W130 for 20 sec each time in the vicinity of ice. The homogenized product was centrifuged at 1500 rpm at 4 °C for 5 min. The supernatant was removed and the sediment was discarded.

Production of mature dendritic cells

After culture, monocyte cells converted to dendritic cells by adding IL-4 and GM-CSF cytokines in a 3-day process. After the initial culture of PBMC cells, the cells were passaged in a new flask with sterile RPMI+10% FBS medium and placed in a CO2 incubator for two hours. The flask was removed from the incubator and the supernatant was discarded, and 10 μl GM-CSF and 10μl IL-4 were added. On the third day, 10 μl GM-CSF and IL-4 were added to the cells again. To convert the dendritic cells to tolerogenic type, the following protocol was implemented: On the fourth day, 15 μL of the somatic M. marshalli parasite with a concentration of 289.91 μg/ml was added to the flask of dendritic cells. After 24 h of exposure to M. marshalli parasite antigens, 10 μl of LPS was added to the flask (5). Eventually, after two days of exposure, the maturity of the dendritic cells was confirmed by observing pseudopods, and the flask contents containing mature dendritic cells were transferred to sterile Falcon.

Production of autologous T lymphocytes

A portion of the PBMC cells were separated from the primary culture, were transferred to a new flask with sterile RPMI+10% FBS medium and were placed in an CO2 incubator for two hours. After two hours, the flask was removed from the incubator and its contents (T-lymphocytes) entered the sterilized Falcon.

Quantitative measurement of TGF-β1 cytokine

Mature dendritic cells and T lymphocytes with ratios of 1:10 and 1:5 were transferred to sterile microplate with sterile RPMI+10% FBS medium and cultured for five days. After 5 d of proximity of dendritic cells with lymphocytes, the contents of wells were transferred to microtubule (31). Then, they were centrifuged at 1500 rpm for 10 min and the supernatant was removed and the contents were stored in freezer at −80 °C until TGF-β1 cytokine was measured. Finally, the quantitative measurement of TGF-β1 cytokine was done by ELISA test (Human TGF beta 1 ELISA Kit) according to the procedure determined by the manufacturer. The test sensitivity in this kit was 2 pq/ml.

Data Analysis

The results were analyzed using SPSS 16 software (Chicago, IL, USA). Descriptive data were composed of the frequency distribution table, central indexes, distribution and percentages. Continuous quantitative data were compared between the cases and control groups using the independent T-test and Chi-Square test. A P<0.05 was considered as the level of significance.

Results

Twenty-five samples were included in this study, including 15 patients with asthma as case group and 10 healthy subjects as control group. The case group consisted of 8 men (53.3%) and 7 women (46.7%), and the control group consisted of 5 men (50%) and 5 women (50%). The mean age of these samples in the case and control groups was 44.87±9.38 and 39.1±10.86 yr, respectively. There was no significant difference between the two groups in terms of age and gender (P>0.05) (Table 1).
Table 1:

Demographics and clinical characteristics of cases and controls

VariableCases n (%)Controls n (%)P-value
Gender
Male8 (53.3%)5 (50%)0.089
Female7 (46.7%)5 (50%)
Age
Age (yr)44.87±9.3839.1±10.860.061
Range20–5520–50-
Family history of diseaseP-value
Parents8 (53.3%)-<0.05
Siblings7 (46.6%)-
2nd and 3rd generation13 (86.6%)-
Clinical symptoms
Shortness of breath11 (73.33%)-<0.05
Cough15 (100%)-
Wheezing12 (80%)-
Chest Tightness10 (66.7%)-
Feelings Of Suffocation9 (60%)-
Nasal congestion9 (60%)-
Rhinorrhea11 (73.33%)-
Total1510-
Demographics and clinical characteristics of cases and controls In examining the clinical symptoms of samples with asthma, all samples suffered from shortness of breath, and coughing. Clinical symptoms in 80% of cases were wheezing, 66.7% had chest tightness and 60% had feelings of suffocation. Furthermore, 53.3% of the samples stated that they had productive coughs with mucus. In addition to asthma, some samples in the case group suffered from other allergic diseases such as allergic rhinitis (66.6%), eczema (20%), hives (26.6%), skin allergies (26.6%), food allergies (33.3%), and drug allergies (13.3%) (Table 1). After preparing mature dendritic cells that became tolerogenic by the somatic antigens of M. marshalli parasite and its proximity to the autologous T cells, they were exposed to these cells for 5 d and were examined for stimulation of T cells. TGF-β1 cytokine was measured to examine the stimulation of T cells by tolerogenic dendritic cells. Mean TGF-β1 level in the case and control groups was 210.2 ± 8.2 and 225.4 ± 6.1 pq/ml, respectively. The results of TGF-β1 level data analysis in the samples of case and control groups showed that TGF-β1 levels in the case group were significantly higher than the control group (P<0.001) (Fig. 1).
Fig. 1:

The Mean±SD of TGF-β1 in the samples analyzed by case and control group

The Mean±SD of TGF-β1 in the samples analyzed by case and control group There was no significant relationship between gender and age of samples and TGF-β1 level in both case and control groups. In addition, there was no significant relationship between family history of asthma and TGF-β1 levels. Moreover, there was no significant relationship between the clinical symptoms of the samples in the case group and TGF-β1 levels. However, there was a significant relationship between TGF-β1 levels in patients with history of comorbidities and allergic rhinitis (P=0.006), skin allergy (P=0.028), food allergy (P=0.004) and eczema (P=0.034). In the case group, TGF-β1 levels in samples with a history of comorbidities and asthma was higher than other samples (Table 2).
Table 2:

The relationship between TGF-β1 levels in patients with history of comorbidities by Asthma

The history of comorbidities by AsthmaN (%)TGF-β1 levels (pq/ml)P-value
EczemaYes3 (20)230.43±0.70.034
No12 (80)224.12±3.91
Eczema
Allergic RhinitisYes10 (66.6)227.91±2.80.006
No5 (33.4)220.34±0.98
HivesYes4 (26.6)226.52±5.220.656
No11 (73.4)224.97±4.2
Skin AllergyYes4 (26.6)230.5±1.040.028
No11 (73.4)223.52±3.45
Food AllergyYes5 (33.4)230.36±0.950.004
No10 (66.6)222.9±2.91
Drug AllergyYes2 (13.3)223.0±3.950.544
No13 (86.7)225.75±4.44
The relationship between TGF-β1 levels in patients with history of comorbidities by Asthma

Discussion

In recent years, the incidence of various types of allergic diseases has increased in many countries (3–5). Asthma is one of the most important allergic diseases. The characteristics of this disease are excessive production of cytokines secreted from Th2 cells, such as Interleukin 4, 5, and 13, and the accumulation of eosinophils in the submucosal intestinal layers (32). By summoning other cells, these cells cause mucosal hyperemia and cause the symptoms of the disease (1, 32). Dendritic cell therapy, also called dendritic vaccine, is a new immunotherapy capability used to treat diseases like cancer. Today, the idea of using dendritic drugs for the treatment of asthma and allergic diseases has also been raised, and parasitic worm antigens are used for converting dendritic cells into T-cells (25, 27, 29, 30). Nematode parasites such as M. marshalli may increase their survival by shifting immune responses to regulatory immunity (18, 21). For example, they interfere with the balance in the Th1/Th2 response and lead to the production of a large number of regulatory cytokines such as IL-10 and TGF-β, as well as imitation of host proteins that convert immune response to immune tolerance (33, 34). Therefore, chronic worm infections may protect the host against allergic diseases due to extensive immunosuppression. This extensive suppression, in general, can lead to a decrease in T cell responsiveness by the activity of T-reg and by regulating the effects of immune cells such as macrophages, dendritic cells, and stromal cells, which leads to the creation of a non-inflammatory environment with high levels of IL-10 and TGF-β (11–13, 22). These cytokines generally result in the inhibition of T and B cell responses. The results of this study showed that TGF-β1 level increased in both case and control groups due to exposure to somatic M. marshalli antigens with lymphocytes. The M. marshalli somatic antigens can shift lymphocyte cells in healthy people and patients to regulatory lymphocyte and provide a basis for treatment and control of asthma. Moreover, history of comorbidities by Asthma with other allergic diseases could significantly increase TGF-β1 levels. Similar studies confirm the results of our study. The effect of ES M. marshalli antigens on peripheral blood mononuclear cells (PBMCs) of 25 healthy samples and 25 samples with asthma was investigated. The expression of TGF-β as a gene secreted from T-reg in co-culture with ES M. marshalli antigen increased significantly in healthy samples and samples with asthma (18). In addition, in an in vivo study, the effect of ES and somatic M. marshalli was examined by investigating the inflammatory cell infiltration into the bronchoalveolar lavage fluid (BALF), pathological changes and IgE response, and it was determined that the pathological changes decreased in the study samples. Furthermore, the levels of inhibitory TGF-β cytokine increased in the tissue homogeneity, serum, and bronchoalveolar lavage fluid, with a significant increase in the homogeneity of lung tissue (35). In addition, many studies were conducted on the effects of other parasite antigens on the immune system. Jin et al. examined murine dendritic cell line DC2.4 and immature dendritic cells of mouse bone marrow with the antigen of Clonorchis sinensis parasite and without this antigen. The rate of TGF-β cytokine production increased significantly (36). In a study, the effect of Schistisoma mansoni antigen was examined on PBMC. TGF-β levels increased in the examined cells (37). S. japonicum antigen was effective in decreasing CD4 + CD25 + T cell production and increasing T-reg in mice. The use of Schistosoma parasite increases the level of IL-10 and decreases the expression of Th2 cytokines and inhibits the progression of asthma (38). The effect of murine filariasis (Litomosoides sigmodontis) was examined on the mouse model of asthma, and the results showed that infection with this parasite significantly reduced the phenotypic aspects of asthma, including eosinophilia and Th2 cytokine secretion. Collecting and culturing splenic mononuclear cells determined that TGF-β levels increased significantly (39).

Conclusion

The proximity of M. marshalli worm antigens to DC cells could increase TGF-β1 levels in the study samples in both case and control groups. Furthermore, TGF-β1 levels in the case group were significantly higher than the control group. Parasitic antigens can create tolerogenic dendritic cells and shift the T lymphocytes to the regulatory type. Therefore, these results can provide the basis for future asthma treatments.
  38 in total

Review 1.  Innate and adaptive immune responses in asthma.

Authors:  Stephen T Holgate
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

Review 2.  Recombinant proteins of helminths with immunoregulatory properties and their possible therapeutic use.

Authors:  Leonardo Nascimento Santos; Luis Gustavo Carvalho Pacheco; Carina Silva Pinheiro; Neuza Maria Alcantara-Neves
Journal:  Acta Trop       Date:  2016-11-18       Impact factor: 3.112

3.  Asthma.

Authors:  Karl-Christian Bergmann
Journal:  Chem Immunol Allergy       Date:  2014-05-22

4.  Pathophysiology of Marshallagia marshalli in experimentally infected lambs.

Authors:  Nona Moradpour; Hassan Borji; Gholamreza Razmi; Mohsen Maleki; Hossein Kazemi
Journal:  Parasitology       Date:  2013-09-05       Impact factor: 3.234

Review 5.  [Dendritic cell therapy].

Authors:  T Takahashi
Journal:  Nihon Rinsho       Date:  2001-12

6.  Helminth infection with Litomosoides sigmodontis induces regulatory T cells and inhibits allergic sensitization, airway inflammation, and hyperreactivity in a murine asthma model.

Authors:  Anna M Dittrich; Annika Erbacher; Sabine Specht; Felix Diesner; Martin Krokowski; Angela Avagyan; Philippe Stock; Birgit Ahrens; Wolfgang H Hoffmann; Achim Hoerauf; Eckard Hamelmann
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

Review 7.  Baseline management of asthma control.

Authors:  O Cavkaytar; B E Sekerel
Journal:  Allergol Immunopathol (Madr)       Date:  2012-12-21       Impact factor: 1.667

Review 8.  Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma.

Authors:  Girolamo Pelaia; Alessandro Vatrella; Maria Teresa Busceti; Luca Gallelli; Cecilia Calabrese; Rosa Terracciano; Rosario Maselli
Journal:  Mediators Inflamm       Date:  2015-03-23       Impact factor: 4.711

9.  Anti-inflammatory Potentials of Excretory/Secretory (ES) and Somatic Products of Marshallagia marshalli on Allergic Airway Inflammation in BALB/c Mice.

Authors:  Sima Parande Shirvan; Hassan Borji; Ahmadreza Movassaghi; Mohammadreza Khakzad; Hamidreza Farzin; Mohsen Maleki; Alireza Haghparast
Journal:  Iran J Parasitol       Date:  2016 Oct-Dec       Impact factor: 1.012

Review 10.  Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?

Authors:  C M U Hilkens; J D Isaacs
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.